The newweight-loss drugs, lorcaserin and phentermine-to piramate slim pickings?

JAMA Internal Medicine

Volumn 174, Issue 4, 2014, Pages 615-619

  Woloshin, Steven ^a   Schwartz, Lisa M ^a  

^a DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORCASERIN; NEW DRUG; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; QYSMIA; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE; DRUG DERIVATIVE; FRUCTOSE; PHENTERMINE; TOPIRAMATE;

ANXIETY; ATTENTION DISTURBANCE; BODY MASS; BODY WEIGHT; CALORIE; CREATININE BLOOD LEVEL; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; EUPHORIA; EXERCISE; FOOD AND DRUG ADMINISTRATION; HUMAN; INSOMNIA; LANGUAGE DISABILITY; MEMORY DISORDER; METABOLIC ACIDOSIS; NEPHROTOXICITY; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); UNITED STATES; VALVULAR HEART DISEASE; WEIGHT REDUCTION; ARTICLE; DRUG EFFECT; FEMALE; MALE; POSTMARKETING SURVEILLANCE;

ANTI-OBESITY AGENTS; BENZAZEPINES; FEMALE; FRUCTOSE; HUMANS; MALE; OBESITY; PHENTERMINE; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WEIGHT LOSS;

EID: 84898490591     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.14629     Document Type: Review

References (14)

1. US Dept of Health and Human Services; Centers for Disease Control and Prevention; National Center for Health Statistics. Health, United States, 2012: table 63, selected health conditions and risk factors. http://www.cdc.gov/nchs/ data/hus /hus12.pdf. Accessed November 14, 2013.
2. Centers for Disease Control and Prevention. Overweight and obesity. http://www.cdc.gov /obesity/data/adult.html. Accessed November 14, 2013.
3. Yaemsiri S, Slining MM, Agarwal SK. Perceived weight status, overweight diagnosis, and weight control among US adults: the NHANES 2003-2008 Study. Int J Obes (Lond). 2011;35(8):1063-1070.
4. Foster-Schubert KE, Alfano CM, Duggan CR, et al. Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese postmenopausal women. Obesity (Silver Spring). 2012;20(8):1628-1638.
5. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight-loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond). 2005;29(10):1153-1167.
6. US Food and Drug Administration. Drug approval package: Belviq (lorcaserin hydrochloride tablets) (NDA) 022529. http://www.accessdata.fda.gov /drugsatfda-docs/nda/2012/022529Orig1s000TOC.cfm.AccessedNovember 15, 2013.
7. US Food and Drug Administration. Drug approval package: Qsymia (phentermine hydrochloride /topiramate) (NDA) 022580 http://www.accessdata.fda. gov/drugsatfda-docs/nda/2012 /022580Orig1s000-qsymia-toc.cfm. Accessed November 15, 2013.
8. Consumer Reports News. Making sense of Belviq's weight-loss claims. http://www.consumerreports.org/cro/news/2013/06 /making-sense-of-belviq-s- weight-loss-claims /index.htm. Accessed November 15, 2013.
9. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Guidance for industry developing products for weight management: revision 1. http://www.fda.gov /downloads/Drugs/.../Guidances/ucm071612.pdf. Accessed November 15, 2013.
10. Yanovski SZ, Yanovski JA. Long-term treatment for obesity: a systematic and clinical review. JAMA. 2013
11. European Medicines Agency. Withdrawal of the marketing authorisation application for Belviq (lorcaserin) (EMA/309180/2013). http://www.ema.europa.eu/ docs/en-GB/document-library/Medicine -QA/2013/05/WC500143811.pdf. Accessed January 10, 2014.
12. European Medicines Agency. Refusal of the marketing authorisation forQsiva (phentermine /topiramate). http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/002350/human-med-001607.jsp&mid= WC0b01ac058001d124. Accessed November 14, 2013.
13. Tran P, Thomas A. Summaryminutes of the Endocrinologic and Metabolic Drugs Advisory Committee meeting, March 28-29, 2012. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303352.pdf. Accessed December 5, 2013.
14. Moore TJ, Furberg CD. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US Food and Drug Administration: the class of 2008. JAMA Intern Med. 2013. doi:10.1001/ jamainternmed.2013.11813.